Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tilvestamab |
| Synonyms | |
| Therapy Description |
Tilvestamab (BGB149) is an monoclonal antibody that targets AXL, which potentially inhibits tumor growth (PMID: 32148495, PMID: 40696160). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tilvestamab | BGB 149|BGB-149|BGB149 | AXL Antibody 5 | Tilvestamab (BGB149) is an monoclonal antibody that targets AXL, which potentially inhibits tumor growth (PMID: 32148495, PMID: 40696160). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04893551 | Phase I | Tilvestamab | A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants | Terminated | NOR | GBR | 2 |